Abstract
BackgroundSingle-agent pembrolizumab treatment of hormone receptor-positive metastatic breast cancer (MBC) has demonstrated modest clinical responses. Little is known about potential biomarkers or mechanisms of response to immune checkpoint inhibitors (ICIs)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have